SomnoMed Director Amrita Singh Blickstead Resigns, Discloses Final Shareholding and Options

SomnoMed's Specialization in Oral Appliance Therapy for Sleep Apnea

Based in Sydney, SomnoMed Limited is an Australian medical device company that designs, manufactures, and markets oral appliances to treat sleep-disordered breathing, including obstructive sleep apnea (OSA). Its main products are custom mandibular advancement devices and other intraoral appliances prescribed by dental and medical professionals as non-invasive treatments for sleep apnea. The company operates globally with a distribution network and manages intellectual property across multiple jurisdictions, prioritizing clinical effectiveness and regulatory compliance in various healthcare markets.

SomnoMed’s business model focuses on delivering tailored oral appliance solutions supported by clinical research and professional training for healthcare providers. Revenue is generated through sales of custom devices to dental and medical practitioners, licensing agreements, and intellectual property partnerships. Listed on the ASX under ticker SOM, the company adheres to continuous disclosure and corporate governance standards required of Australian listed entities.

Shareholding Details of Director Amrita Singh Blickstead Upon Departure

When Amrita Singh Blickstead resigned as director on 27 July 2026, she held 2,392,364 ordinary fully paid shares in SomnoMed. This substantial equity stake reflects her prior confidence in the company’s operations and strategic direction. The Final Director's Interest Notice transparently reports her ownership at the time of her board exit, informing ASX participants and investors of her interests.

Besides ordinary shares, Blickstead held 1,885,000 options and 600,000 zero exercise price options as of her cessation date. These options represent potential future economic interests and likely stem from equity incentive or other arrangements during her board tenure. The treatment of these options post-departure—including vesting, lapse, or conversion—depends on the terms of the option agreements and company policies.

Mandatory Regulatory Disclosure for Director Resignations

SomnoMed’s Final Director's Interest Notice complies with ASX Listing Rule 3.19A.3 and section 205G of the Corporations Act, which require disclosure of a director’s securities interests upon resignation. This ensures the market is fully informed of the director’s final shareholdings and related interests. The notice must include all registrable holdings, beneficial interests, and contractual interests to maintain investor transparency.

The lodged notice shows no entries in Part 2 (interests not registered in the director’s name) or Part 3 (contractual interests), indicating no additional relevant interests beyond those disclosed in Part 1. The prior notice for Blickstead was dated 4 December 2025, making this filing an update reflecting her departure approximately seven months later. Accurate and complete disclosures uphold the integrity of the ASX’s regulatory framework.

Effect of Blickstead’s Resignation on SomnoMed’s Board Structure

Blickstead’s resignation on 27 July 2026 alters SomnoMed’s board composition. The announcement does not specify whether her departure was planned or unexpected, nor does it mention any replacement appointments. Board changes are significant for investors, as directors provide expertise, governance oversight, and strategic guidance. Such transitions can influence market perceptions of company stability and direction.

Following a director’s exit, SomnoMed must ensure compliance with ASX listing rules regarding board composition and skills mix. The company is expected to disclose any board reconstitution or appointment processes promptly. Continuous disclosure obligations require timely market notification of material changes to the board or senior management, enabling investors to make informed decisions.

Summary of Share and Option Holdings at Resignation

The Final Director's Interest Notice offers a detailed overview of Blickstead’s financial interests at resignation. Her holding of 2,392,364 ordinary fully paid shares represents a significant equity stake. Although the notice does not specify percentage ownership, investors may compare this figure with SomnoMed’s total issued capital disclosed in recent reports to gauge its relative size.

The disclosed options include 1,885,000 options with unspecified exercise prices and 600,000 zero exercise price options, which confer rights to acquire shares without payment of a strike price upon satisfying conditions. The notice lacks details on exercise prices, vesting schedules, or other key terms. The post-resignation treatment of these options depends on contractual provisions, including vesting, acceleration, or lapse clauses. Investors should seek further information from SomnoMed for a complete understanding.

ASX Compliance and Disclosure Framework

SomnoMed’s filing of the Final Director's Interest Notice demonstrates adherence to ASX continuous disclosure rules. Under Listing Rule 3.19A.3, directors must lodge notices of their securities interests within specified timeframes, including a final notice upon cessation. These rules foster investor confidence by ensuring transparency of director shareholdings. The Corporations Act section 205G provides the statutory foundation for these disclosures alongside ASX rules.

The standardised Appendix 3Z form requires systematic reporting of registered holdings, beneficial interests, and contractual interests. Introduced in 2001, it remains the primary tool for capturing director interest information. SomnoMed’s timely lodgement following Blickstead’s 27 July 2026 departure fulfills its disclosure obligations. The ASX monitors compliance and may enforce penalties if breaches occur.

Importance of Director Shareholdings for Investor Confidence

Director shareholdings are often viewed by investors as indicators of confidence in company prospects and governance. Blickstead’s holding of over 2.3 million shares at resignation suggests a material financial commitment to SomnoMed’s success. Such stakes can signal alignment between directors and shareholders, supporting perceptions of strong governance and strategic conviction.

Conversely, a director’s departure with significant shareholdings may prompt investor questions about the reasons behind the exit or changes in confidence. The regulatory notice provides no additional context, leaving investors to interpret the implications. SomnoMed may release further communications if the departure materially affects the company. Investors should watch for updates providing more detail on this transition.

Market Impact and Investor Considerations

A director resignation at a listed company like SomnoMed can affect governance, strategic continuity, and investor sentiment. Shareholders and potential investors in the medical device sector should consider director departures as signals to reassess investment positions or seek further information on company strategy and management stability. The lack of commentary in the notice means investors should monitor SomnoMed for subsequent announcements regarding board changes and their implications.

Investors evaluating SomnoMed should also consider the timing of the resignation relative to earnings releases, strategic milestones, or market conditions. The company’s continuous disclosure obligations mandate prompt reporting of material board changes. Investors may contact SomnoMed’s investor relations for additional insights beyond the regulatory filing.

Considerations Regarding Options and Future Equity Interests

The disclosed options—1,885,000 at unspecified exercise prices plus 600,000 zero exercise price options—represent potential future shareholdings contingent on conditions after Blickstead’s departure. The notice does not detail exercise prices, vesting, or other terms. Investors interested in the departing director’s full economic interests should request further details from SomnoMed.

Post-resignation treatment of unvested or unexercised options depends on option agreements and board discretion. Options may vest immediately, accelerate, lapse, or be subject to other terms, impacting the director’s economic stake. The ultimate shareholding resulting from option exercise or lapse may differ significantly from the figures disclosed in this Final Notice.